Studies on doctor education in the opioid epidemic were flawed, and hindsight, as they say, is 20/20. And although the FDA has lobbied heavy criticism and the pharmaceutical industry has paid fines, they are not without blame. They took years to investigate the makers and distributors of Oxycontin. Instead of protecting consumers, the federal agency instead left its own bumbling paper trail for opioid education oversight, according to a New York Times report.
The FDA, documents reveal, did little to stop overprescribing and, in fact, created a study that failed to be accurate by design, according to Caleb Alexander, the senior author of the study. “It’s unclear why the FDA didn’t insist upon a more scientifically rigorous evaluation of this safety program.” This means that it’s unclear if any studies were correct.